University of Kentucky Sanders-Brown Center on Aging
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jicha, Gregory
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
SMArT-HS, NCT04120766: Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

Active, not recruiting
2
64
US
Nicorandil, Placebo
Gregory Jicha, MD, PhD, National Institute on Aging (NIA)
Dementia, Mild Cognitive Impairment
09/26
11/26
LiBBY, NCT05644262: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Recruiting
2
150
US
T2:C100, TRC/CBD oral combination, Placebo
University of Southern California, Medical University of South Carolina, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA)
Agitation, Dementia
12/25
12/25
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
MarkVCID, NCT06284213: Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium

Active, not recruiting
N/A
1892
US
No interventions
Massachusetts General Hospital, Duke University, Johns Hopkins University, University of New Mexico, University of Southern California, University of Kentucky, Rush University Medical Center, University of Maryland, Baltimore, University of California, San Francisco, University of California, Los Angeles, University of California, Davis, University of Texas, The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center, Houston, Mayo Clinic, University of Mississippi Medical Center, Washington University School of Medicine, Olive View-UCLA Education & Research Institute
Cognitive Impairment, Dementia
07/27
07/27
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
Jones, Keisha
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
NCT05250908: INTIBIA Pivotal Study

Active, not recruiting
N/A
208
Europe, US
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Coloplast A/S
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
06/25
06/26

Download Options